Who Owns Summit Therapeutics Stock?
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 17.58%
- Held by insiders
- 80.89%
- Institutional holders
- 331
- Institutions 17.6%
- Insiders 80.9%
- Public and other 1.5%
Who owns Summit Therapeutics stock?
Institutional investors own about 17.6% of Summit Therapeutics's shares, spread across 331 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 80.89% of SMMT.
The largest institutional holders are Baker Bros. Advisors, LP (4.10%), FMR, LLC (1.26%) and State Street Corporation (1.19%). Together, the top 10 institutions control 11.3% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their SMMT positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of SMMT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Baker Bros. Advisors, LP | 32.79M | 4.10% | -9.9% |
| FMR, LLC | 10.04M | 1.26% | -7.5% |
| State Street Corporation | 9.54M | 1.19% | +35.7% |
| Blackrock Inc. | 9.53M | 1.19% | -1.3% |
| Vanguard Capital Management LLC | 5.73M | 0.72% | +0.4% |
| UBS Group AG | 5.23M | 0.65% | +42.2% |
| Vanguard Portfolio Management LLC | 5.04M | 0.63% | -3.6% |
| Goldman Sachs Group Inc | 4.51M | 0.56% | +1352.5% |
| Price (T.Rowe) Associates Inc | 3.89M | 0.49% | -53.0% |
| Point72 Asset Management, L.P. | 3.70M | 0.46% | +371.6% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of SMMT
| Fund | Shares | % Held |
|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 7.85M | 0.98% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.71M | 0.46% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.67M | 0.33% |
| T. Rowe Price Health Sciences Fund, Inc. | 2.53M | 0.32% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.05M | 0.26% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.78M | 0.22% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.69M | 0.21% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.07M | 0.13% |
| abrdn Healthcare Investors | 1.06M | 0.13% |
| iShares Trust-iShares Biotechnology ETF | 1.01M | 0.13% |
Frequently asked questions
Who is the largest shareholder of Summit Therapeutics?
Baker Bros. Advisors, LP is the largest institutional shareholder of SMMT, owning 4.10% of shares outstanding (32.79M shares) as of its latest 13F filing.
What percentage of Summit Therapeutics is owned by institutions?
Institutions own about 17.6% of SMMT shares and 92.0% of the public float.
How much of Summit Therapeutics do insiders own?
Insiders, such as officers and directors, own about 80.89% of SMMT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.